S

Shandong Sinobioway Biomedicine Co Ltd
SZSE:002581

Watchlist Manager
Shandong Sinobioway Biomedicine Co Ltd
SZSE:002581
Watchlist
Price: 11.88 CNY -5.64% Market Closed
Market Cap: 7.8B CNY
Have any thoughts about
Shandong Sinobioway Biomedicine Co Ltd?
Write Note

Shandong Sinobioway Biomedicine Co Ltd
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Shandong Sinobioway Biomedicine Co Ltd
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
S
Shandong Sinobioway Biomedicine Co Ltd
SZSE:002581
Operating Income
-ÂĄ400.7m
CAGR 3-Years
-16%
CAGR 5-Years
-12%
CAGR 10-Years
N/A
Fufeng Group Ltd
HKEX:546
Operating Income
ÂĄ3.1B
CAGR 3-Years
47%
CAGR 5-Years
2%
CAGR 10-Years
N/A
G
GHW International
HKEX:9933
Operating Income
ÂĄ18.8m
CAGR 3-Years
-15%
CAGR 5-Years
-30%
CAGR 10-Years
N/A
Ningxia Baofeng Energy Group Co Ltd
SSE:600989
Operating Income
ÂĄ8.7B
CAGR 3-Years
2%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Zhejiang XinAn Chemical Industrial Group Co Ltd
SSE:600596
Operating Income
ÂĄ162.5m
CAGR 3-Years
-59%
CAGR 5-Years
-24%
CAGR 10-Years
-5%
A
Anhui Jinhe Industrial Co Ltd
SZSE:002597
Operating Income
ÂĄ583m
CAGR 3-Years
-14%
CAGR 5-Years
-7%
CAGR 10-Years
13%
No Stocks Found

Shandong Sinobioway Biomedicine Co Ltd
Glance View

Market Cap
7.8B CNY
Industry
Chemicals

Shandong Sinobioway Biomedicine Co., Ltd. engages in the research and development, manufacture, and sale of chemical raw materials, chemical and pharmaceutical products. The company is headquartered in Beijing, Beijing and currently employs 653 full-time employees. The company went IPO on 2011-05-20. The firm's main products include encyclopedia, anferon, triethyl orthoformate, trimethyl orthofomate, trimethyl orthoacetate and related secondary products, among others. The firm distributes its products within domestic market and to overseas markets.

Intrinsic Value
3.08 CNY
Overvaluation 74%
Intrinsic Value
Price
S

See Also

What is Shandong Sinobioway Biomedicine Co Ltd's Operating Income?
Operating Income
-400.7m CNY

Based on the financial report for Jun 30, 2024, Shandong Sinobioway Biomedicine Co Ltd's Operating Income amounts to -400.7m CNY.

What is Shandong Sinobioway Biomedicine Co Ltd's Operating Income growth rate?
Operating Income CAGR 5Y
-12%

Over the last year, the Operating Income growth was -122%. The average annual Operating Income growth rates for Shandong Sinobioway Biomedicine Co Ltd have been -16% over the past three years , -12% over the past five years .

Back to Top